A Positive GMP Experience: Replacing Functional Handoffs With Project-Based Execution

Traditional CDMO execution can fragment a program into sequential tasks owned by separate functions: Product Development designs, Manufacturing runs, Quality Control tests, and Quality Assurance reviews. The integrated-execution poster argues that this siloed model creates a predictable failure point at the development-to-GMP handoff, when hidden assumptions, manufacturability constraints, method issues, and quality expectations surface late.

Bend Bioscience proposes a project-based alternative in which knowledge is built continuously with input from R&D, Manufacturing, QC, QA, and the sponsor. The model emphasizes early collaboration, shared ownership, streamlined communication, and “right-sized” controls that add scientific and quality value rather than treating GMP as paperwork. In the poster’s illustrative comparison, an integrated model delivers first-in-human supplies in less than six months versus 10-12 months for a typical siloed model. Issues are intended to be found earlier through shared oversight; when deviations or technical problems do occur, the relevant functions and sponsor can engage quickly around root cause and path forward.

The poster reports three years of results with zero delays to toxicology or clinical supply delivery and zero rejected batches, along with successful delivery of projects whose timelines competitors declined. The white paper opportunity is to define what an integrated GMP operating model looks like in practice and why it can improve both speed and predictability: fewer transactional handoffs, better preservation of product knowledge, earlier technical problem solving, and a culture in which every activity is expected to add science, quality, or knowledge value.